Proteonomix Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial with UMK-121 in End-Stage …

PARAMUS, N.J.--(BUSINESS WIRE)--

Proteonomix, Inc. (PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that Numoda Corporation will provide a range of specific clinical trial services for a Proteonomix-sponsored Phase 1 clinical trial with its patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD). Numoda is leading provider of clinical trial information and logistics services to life sciences companies.

Initiating this clinical trial represents a major milestone for Proteonomix and we are delighted to report additional progress toward this goal, said Proteonomix Chief Technology Officer Steven Byle. UMK-121 combines two existing FDA-approved drugs with the intention of mobilizing mesenchymal stem cells from bone marrow to the peripheral circulation. This proprietary drug combination is designed to reduce inflammation and increase angiogenesis to restore liver function, potentially extending the life of ESLD patients awaiting liver transplant. We hope to begin this trial in the upcoming months.

Earlier this month, Proteonomix signed a master agreement with Numoda for clinical trial services. In August, the U.S. Food and Drug Administration granted Proteonomix permission to conduct a Phase 1 clinical trial with UMK-121 in patients with ESLD.

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and plans to file an IND application for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at http://www.proteonomix.com and http://www.proteoderm.com.

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Read more from the original source:
Proteonomix Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial with UMK-121 in End-Stage ...